Please use this identifier to cite or link to this item:
Title: Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
Author: Hanna, Catherine R.
Robles Zurita, José A.
Briggs, Andrew
Harkin, Andrea
Kelly, Caroline
McQueen, John
Allan, Karen
Pearson, Sarah
Hollander, Henrik
Glimelius, Bengt
Salazar Soler, Ramón
Segelov, Eva
Saunders, Mark
Iveson, Tim
Jones, Robert J.
Boyd, Kathleen A.
Keywords: Càncer colorectal
Economia de la salut
Cancer chemotherapy
Medical economics
Issue Date: 1-Sep-2021
Publisher: Elsevier
Abstract: Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and methods: Individual cost-utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost-utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial.
Note: Reproducció del document publicat a:
It is part of: Clinical Colorectal Cancer, 2021, vol. 20,num. 3, p. 236-244
Related resource:
ISSN: 1533-0028
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PIIS1533002821000293.pdf962.87 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons